Literature DB >> 1659627

Low expression of beta 1, alpha 2 and alpha 3 subunits of VLA integrins in malignant mammary tumours.

M Pignatelli1, A M Hanby, G W Stamp.   

Abstract

The Very Late Antigens (VLAs) are alpha beta heterodimeric transmembrane proteins mediating cell-substratum as well as cell-cell interactions. Changes in their expression and/or function seem to occur in a number of invasive carcinomas and may at least in part explain their abnormal patterns of growth and differentiation. Using monoclonal antibodies to the beta 1 (DH12, A1A-5), alpha 2 (B1.515) and alpha 3 (E1.56) chains, VLA-2 (alpha 2 beta 1) and VLA-3 (alpha 3 beta 1) were studied on cryostat sections of three fibroadenomas and 43 invasive breast carcinomas (29 ductal, 14 lobular) by the avidin-biotin complex immunoperoxidase technique. In non-neoplastic breast tissue and in fibroadenomas VLA-2 and VLA-3 were expressed by myoepithelial cells and on the basolateral surface of the luminal cells. There was weak or absent expression of alpha 2, alpha 3 and the common beta 1 chain in the majority of invasive carcinomas compared to the adjacent normal breast epithelium and preinvasive (in-situ) carcinomas. In addition, the expression of the alpha 2 chain of VLA-2 was reduced significantly (P less than 0.005) in the poorly differentiated ductal breast carcinomas (Grade III) compared to the well (Grade I) and moderately (Grade II) differentiated ductal tumours. These data give further evidence that loss or down-regulation of VLA-2 and VLA-3 occur relatively frequently in invasive cancers, and, at least in the invasive ductal breast carcinomas. Loss of an extracellular matrix receptor controlling growth and differentiation seems to be one of the abnormalities underlying the progression towards an undifferentiated morphology.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1659627     DOI: 10.1002/path.1711650106

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  35 in total

Review 1.  Physiological and pathological roles of alpha3beta1 integrin.

Authors:  Tsutomu Tsuji
Journal:  J Membr Biol       Date:  2004-08-01       Impact factor: 1.843

2.  Regulation of keratin and integrin gene expression in cancer and drug resistance.

Authors:  N Daly; P Meleady; D Walsh; M Clynes
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

3.  Three-dimensional culture models of mammary gland.

Authors:  Jonathan J Campbell; Christine J Watson
Journal:  Organogenesis       Date:  2009-04       Impact factor: 2.500

4.  Modulation of in vivo migratory function of alpha 2 beta 1 integrin in mouse liver.

Authors:  W C Ho; C Heinemann; D Hangan; S Uniyal; V L Morris; B M Chan
Journal:  Mol Biol Cell       Date:  1997-10       Impact factor: 4.138

5.  Invasive potentials of gastric carcinoma cell lines: role of alpha 2 and alpha 6 integrins in invasion.

Authors:  N Koike; T Todoroki; H Komano; T Shimokama; S Ban; T Ohno; K Fukao; T Watanabe
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

6.  Expression of beta 1 integrins in non-neoplastic mammary epithelium, fibroadenoma and carcinoma of the breast.

Authors:  G Mechtersheimer; M Munk; T Barth; K Koretz; P Möller
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

7.  Expression of focal adhesion kinase and alpha5 and beta1 integrins in carcinomas and its clinical significance.

Authors:  Jian-Min Su; Lu Gui; Yi-Ping Zhou; Xi-Liang Zha
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

8.  Integrins as differential cell lineage markers of primary liver tumors.

Authors:  R Volpes; J J van den Oord; V J Desmet
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

9.  Expression of the VLA beta 1 integrin family in bladder cancer.

Authors:  M Liebert; R Washington; J Stein; G Wedemeyer; H B Grossman
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

10.  Alterations in integrin expression modulates invasion of pancreatic cancer cells.

Authors:  Naomi Walsh; Martin Clynes; John Crown; Norma O'Donovan
Journal:  J Exp Clin Cancer Res       Date:  2009-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.